It has been demonstrated that CD4 T-cell populations isolated from CLL patients are skewed at a molecular and phenotypic level towards a Th1 profile after a brief in vitro dose of ibrutinib, confirming a T-cell-specific effect of this agent [30,31]. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.